Patent SG-11201806392X-A (SG)
Title: Personalized delivery vector-based immunotherapy and uses thereof
Inventor: PETIT ROBERT
IPC: C12N15/74
Filed: 2017-01-27
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/132547 Al 3 August 2017 (03.08.2017) WIPO I PCT (51) International Patent Classification: C12N 15/74 (2006.01) A61K 35/74 (2006.01) C12N 15/66 (2006.01) A61K 39/00 (2006.01) C07K 5/10 (2006.01) A61K 48/00 (2006.01) C07K 14/705 (2006.01) (21) International Application Number: PCT/US2017/015403 (22) International Filing Date: 27 January 2017 (27.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/287,871 27 January 2016 (27.01.2016) US (71) Applicant: ADVAXIS, INC. [US/US]; 305 College Road East, Princeton, New Jersey 08540 (US). (72) Inventors: PETIT, Robert; 149 Parsons Lane, Newtown, Pennsylvania 18940 (US). PERRY, Kyle; 2233 Town Court North, Lawrenceville, New Jersey 08648 (US). PRINCIOTTA, Michael F.; 222 Mercer Street, Hight- stown, New Jersey 08520 (US). (74) Agents: SCHILLING, Stephen H. et al.; Alston & Bird LLP, 101 South Tryon Street, Suite 4000, Charlotte, North Carolina (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) — (54) Title: PERSONALIZED DELIVERY VECTOR-BASED IMMUNOTHERAPY AND USES THEREOF 11111111111111011101111111111101011111011101110111011001111111111111111110111111 Tu mo r Vo lu me ( mm 3) 3000 2000 1000 0 - N- LmddA274 -v- Neo 12 -0- Frameshift 1 - 6- Frameshift 2 W O 20 17 / 13 25 47 Al 10 15 20 25 30 Days post inoculation Fig. 28 (57) : Disclosed herein is a personalized immunotherapy composition for a subject having a disease or condition, including therapeutic vaccine delivery vectors and methods of making the same comprising gene expression constructs expressing frameshift- mutation-derived peptides associated with one or more neo-epitopes encoded by nucleic acid sequences comprising at least one frameshift mutation, wherein the frameshift mutation is specific to a subject's cancer or unhealthy tissue. A delivery vector of this disclosure includes bacterial vectors; or viral vectors, or peptide vaccine vectors; or DNA vaccine vectors including Listeria bacterial vectors comprising one or more fusion proteins comprising one or more frameshift-mutation-derived peptides comprising one or more neo-epitopes present in disease-bearing biological samples obtained from the subject. Disclosed are also methods of using these compositions for inducing an immune response against a disease or condition, including a tumor or cancer, or an infection in the subject.